CRISPR-Based TRED-I Enhances Immune Response to Cancer
New Technology Makes Cancer Easier for Immune System to Find and Destroy
Tags: Hokkaido University, Japan, Healthcare & Lifesciences
Researchers from Hokkaido University, Toyo University, and the University of Missouri have developed a CRISPR-based technology that increases the visibility of cancer cells to the immune system. The technology, called TRED-I, reactivates genes like NLRC5 to boost MHC class I molecule levels in cancer cells, making them more detectable to CD8+ T cells. In animal models, TRED-I significantly reduced tumor size and enhanced the efficacy of existing immunotherapies, even affecting distant metastases. This innovative approach shows promise for treating cancers that are resistant to current therapies. The research aims to develop direct delivery methods for the TRED-I system in cancer patients, offering hope for more effective treatments.
IP Type or Form Factor: Material; Software & Algorithm
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Biotechnology; Healthcare Provider
